STAT3 and cancer: Collectively, our study demonstrated that DYRK1A could positively regulate the STAT3/EGFR/Met axis and DYRK1A suppression could enhance the anti‐cancer activity of AZD9291 via STAT3 pathway in EGFR wild‐type NSCLC cells.